D-1494-2020 Class II Terminated
FDA drug recall D-1494-2020 was initiated by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc on Aug 4, 2020 and is designated Class II. Reason for recall: Subpotent drug: Out of specification for assay at the 15-month test interval. The recall status is terminated (terminated Sep 22, 2021). Affected quantity: 7416 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 19, 2020
- Initiation Date
- Aug 4, 2020
- Termination Date
- Sep 22, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7416 bottles
Product description
Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), Rx only, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0810-16
Reason for recall
Subpotent drug: Out of specification for assay at the 15-month test interval.
Distribution pattern
Nationwide USA
Code information
Lot: B973, Exp 11/20
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1494-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026